From Native Lymphocytes to CAR-T Therapy
A brief introduction to key concepts in Chimeric antigen receptor T cell therapy, from the role of T cells in the immune system and the mechanisms by which they exert their function, through the characteristics of T cell receptors, to the basics of CAR-T technology, its application and its current challenges.
Table of Contents
- An introduction to lymphocytes
- Antigen recognition by T-cell receptors
- An introduction to immunoreceptors
- T-cell receptors (TCRs)
- CAR-T for cancer treatment
- CAR-T for the treatment of relapse refractory multiple myeloma
- Some issues associated with CAR-T cell therapies
- Challenges in applying CAR-T therapies to solid tumours
- More on the challenge of recruiting CAR-T cells to solid tumours
- The potential of CAR-T therapy for autoimmune diseases
1. An introduction to lymphocytes
By Prof. Herman Waldmann – University of Oxford, UK
An excerpt from Introduction to the immune system
-
Play An introduction to lymphocytes
2. Antigen recognition by T-cell receptors
By Prof. Herman Waldmann – University of Oxford, UK
An excerpt from Antigen recognition in the immune system
-
Play Antigen recognition by T-cell receptors
3. An introduction to immunoreceptors
By Prof. Anton van der Merwe – University of Oxford, UK
An excerpt from Immunoreceptors
-
Play An introduction to immunoreceptors
4. T-cell receptors (TCRs)
By Prof. Anton van der Merwe – University of Oxford, UK
An excerpt from Immunoreceptors
-
Play T-cell receptors (TCRs)
5. CAR-T for cancer treatment
By Prof. Sebastian Kobold – Ludwig-Maximilians-Universität München, Germany
An excerpt from Mode of action of T cells engineered with CAR or TCR for cancer treatment
-
Play CAR-T for cancer treatment
6. CAR-T for the treatment of relapse refractory multiple myeloma
By Prof. Paul G. Richardson – Harvard Medical School, USA
An excerpt from The evolving role of novel and next generation therapies in the management of multiple myeloma: relapse refractory multiple myeloma 2
-
Play CAR-T for the treatment of relapse refractory multiple myeloma
7. Some issues associated with CAR-T cell therapies
By Prof. Sebastian Kobold – Ludwig-Maximilians-Universität München, Germany
An excerpt from Mode of action of T cells engineered with CAR or TCR for cancer treatment
-
Play Some issues associated with CAR-T cell therapies
8. Challenges in applying CAR-T therapies to solid tumours
By Prof. Sebastian Kobold – Ludwig-Maximilians-Universität München, Germany
An excerpt from Mode of action of T cells engineered with CAR or TCR for cancer treatment
-
Play Challenges in applying CAR-T therapies to solid tumours
9. More on the challenge of recruiting CAR-T cells to solid tumours
By Prof. Ann Ager – Cardiff University, UK
An excerpt from Lymphocyte homing: getting lymphocytes to the right place at the right time
-
Play More on the challenge of recruiting CAR-T cells to solid tumours
10. The potential of CAR-T therapy for autoimmune diseases
By Dr. Marko Radic – University of Tennessee, USA
An excerpt from The potential of CAR T cells for the treatment of autoimmune diseases
-
Play The potential of CAR-T therapy for autoimmune diseases